Cellular and Humoral Response After Induction of Protection and After Finishing Hymenoptera Venom Immunotherapy
Biomolecules · 2024
DOI: 10.3390/biom14121494 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Ajda Demšar Luzar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Clinical Immunology and Molecular Genetics, University Clinic of Respiratory and Allergic Diseases Golnik, 4204 Golnik, Slovenia. Hauptthemen laut MEDLINE: Bee Venoms, Insect Bites and Stings, Desensitization, Immunologic. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Slovenian Research and Innovation Agency.
Abstract (Originalsprache)
Hymenoptera venom allergy (HVA) is an IgE-mediated hypersensitivity reaction caused by Hymenoptera species stings (honeybee, vespid, or ant). The only effective treatment is Hymenoptera venom immunotherapy (VIT). Our study aimed to evaluate whether humoral and cellular biomarkers measured before, during, and after honeybee VIT are associated with the success of VIT, which was assessed by the response to a sting challenge one year after finishing VIT. In this prospective study, blood biomarkers of 25 patients undergoing honeybee VIT at the referral center in Slovenia were evaluated. A controlled honeybee sting challenge confirmed successful VIT in 20 of 25 (80%) patients. Honeybee venom (HBV) recombinant allergen profiles, evaluated before the treatment, were comparable between responders and non-responders. Longitudinal follow-up, up to 1 year after finishing VIT, showed that the immune responses do not differ significantly between patients with successful VIT and treatment failure. Those responses were characterized by decreased sIgE, tIgE, and BST, whereas sIgG4 levels increased. The basophil sensitivity also significantly decreases after VIT in both groups of patients. The analyzed biomarker which correlated considerably with treatment failure was higher basophil sensitivity to allergen stimulation before VIT. Similarly, systemic adverse events (SAEs) during the build-up phase of VIT correlated with treatment failure. Our study demonstrated similar sensitization profiles, and humoral and basophil immune responses to immunotherapy, in two different well-characterized groups of patients, one with successful VIT and the other with treatment failure. Notably, only high basophil sensitivity measured before VIT and SAEs during VIT were significantly associated with VIT failure, and both have the potential to be predictors of VIT failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory for Clinical Immunology and Molecular Genetics, University Clinic of Respiratory and Allergic Diseases Golnik, 4204 Golnik, Slovenia.
- Biotechnical Faculty, University of Ljubljana, 1000 Ljubljana, Slovenia.
- Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
- Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia.
- Faculty of Medicine, University of Maribor, 2000 Maribor, Slovenia.
ORCID-Profile: Matija Rijavec, Mitja Košnik, Urška Bidovec-Stojković, Peter Kopač
Förderung
- Slovenian Research and Innovation Agency
Zitieren
APA
Demšar Luzar, A., Rijavec, M., Košnik, M., Bidovec-Stojković, U., Debeljak, J., Zidarn, M., Kopač, P., & Korošec, P. (2024). Cellular and Humoral Response After Induction of Protection and After Finishing Hymenoptera Venom Immunotherapy. Biomolecules. https://doi.org/10.3390/biom14121494
Vancouver
Demšar Luzar A, Rijavec M, Košnik M, Bidovec-Stojković U, Debeljak J, Zidarn M, et al. Cellular and Humoral Response After Induction of Protection and After Finishing Hymenoptera Venom Immunotherapy. Biomolecules. 2024. doi:10.3390/biom14121494
BibTeX
@article{DemarLuzar2024,
author = {Demšar Luzar, Ajda and Rijavec, Matija and Košnik, Mitja and Bidovec-Stojković, Urška and Debeljak, Jerneja and Zidarn, Mihaela and Kopač, Peter and Korošec, Peter},
title = {Cellular and Humoral Response After Induction of Protection and After Finishing Hymenoptera Venom Immunotherapy},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14121494}
}
EUVIMED